← Leaderboards
Chinthalapally V. Rao
University Of Oklahoma Hlth Sciences Ctr
$1,694,633
Attributed
$1,694,633
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $890.9K · FY2015–20$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$1,694,633 · 2
By mechanism
N01$1,694,633 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Oklahoma Hlth Sciences Ctr
Same institution · by research overlap
- Madeleine W. Cunningham$13,323,044
- Chinthalapally Rao$10,981,534
Others in their field
Top investigators on “Pre-Clinical”
- Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
- Dennis R. Burton · Scripps Research Institute$257,157,696
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barton F Haynes · Duke University$186,001,832
- David Heimbrook · Leidos Biomedical Research, Inc.$151,740,590
- Reisa A. Sperling · Banner Health$137,047,788
Research focus
Pre-ClinicalCessation Of LifeChemopreventive AgentMalignant NeoplasmsClinical TrialsBiological MarkersColorectal Cancer PreventionColorectal CancerDoseToxic EffectHigh RiskPharmaceutical PreparationsCancer EtiologyBindingBaseAllelesAttentionAtherosclerosisAge-YearsAdaptive Immune ResponseCd8-Positive T-LymphocytesCancer VaccinesCell DeathAspirin
Grant awards (3)
BASE TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS; TASK ORDER TITLE: EFGR AND KRAS VACCINE$890,873
N01 · FY2020 · CA · contact PI
PREVENTION OF COLORECTAL CANCER BY ONC201$205,656
N01 · FY2016 · CA · contact PI
IGF::OT::IGF COMBINATION OF ASPIRIN OR NAPROXEN WITH OMERPRAZOLE FOR COLORECTAL CANCER CHEMOPREVENTION WITH CLINICALLY RELEVANT DOSES$598,104
N01 · FY2015 · CA · contact PI